<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511004</url>
  </required_header>
  <id_info>
    <org_study_id>999907197</org_study_id>
    <secondary_id>07-I-N197</secondary_id>
    <nct_id>NCT00511004</nct_id>
  </id_info>
  <brief_title>Effect of Albendazole Dose on Treatment of Lymphatic Filariasis</brief_title>
  <official_title>Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Kerala, India. It will determine whether a new treatment regimen
      of albendazole and diethylcarbamazine (DEC) for lymphatic filariasis can eliminate the
      disease more quickly than the standard regimen. Lymphatic filariasis is caused by infection
      with very small parasitic worms that are spread by mosquitoes. The disease can cause swelling
      of the arms, legs, breast and scrotum and can progress to permanent swelling of the legs or
      arms called elephantiasis. The study will see if a higher and more frequent dose of
      albendazole is better at clearing filarial worms from the blood than the current treatment.

      Healthy people between 18 and 55 years of age who are in good health and who are infected
      with filarial worms may be eligible for this study.

      Participants undergo the following procedures:

      3-day hospital stay at the Filariasis Chemotherapy Unit of the T.D. Medical College Hospital
      in Kerala, India

        -  Random assignment to receive either: 400 mg albendazole and DEC 300 mg given once a year
           for 2 years (standard treatment); or 800 mg albendazole and DEC 300 mg given once a year
           for 2 years; or 800 mg albendazole and DEC 300 mg given twice a year for 2 years.

        -  Urine pregnancy test for women of childbearing age .

        -  Ultrasound test to look for filarial worms.

        -  Treatment dose.

        -  Monitoring for symptoms

           6-month 3-day hospital stay

        -  Medical history, physical examination and blood test.

        -  Repeat ultrasound in subjects whose first ultrasound detected adult worms.

        -  Treatment dose for subjects receiving medicine every 6 months.

        -  Urine pregnancy test for women of childbearing age.

           1-year 3-day hospital stay

        -  Medical history, physical examination and blood test.

        -  Treatment dose.

        -  Repeat ultrasound in subjects whose first ultrasound detected adult worms.

        -  Urine pregnancy test for women of childbearing age.

           18-month 3-day hospital stay

        -  Medical history, physical examination and blood test.

        -  Treatment dose for subjects receiving medicine every 6 months.

        -  Urine pregnancy test for women of childbearing age.

           24-month 3-day hospital stay

        -  Medical history, physical examination and blood test.

        -  Treatment dose.

        -  Repeat ultrasound in subjects whose first ultrasound detected adult worms.

        -  Urine pregnancy test for women of childbearing age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Albendazole and diethylcarbamazine (DEC) are currently used in combination for annual mass
      treatment of lymphatic filariasis in all parts of the world except Africa. Although the drugs
      have been donated, the cost of such programs is very high and has proven to be a major
      impediment to the success of programs in many countries with limited financial resources.
      Data from albendazole treatment of other filarial infections and one study comparing single
      to multi-dose DEC/albendazole in lymphatic filariasis suggest that increased dose and/or
      frequency of albendazole dosing may be more effective in clearing microfilariae. In this
      study, 75 volunteers with microfilaremic Brugia malayi infection will be randomized to
      receive standard annual therapy (albendazole 400 mg + DEC 300 mg), annual therapy with
      increased dosing of albendazole (albendazole 800 mg + DEC 300 mg), or semiannual therapy with
      an increased albendazole dose (albendazole 800 mg + DEC 300 mg). Microfilarial levels will be
      followed every 6 months for 2 years to determine whether the higher dose, and/or the more
      frequent regimen, is more effective.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microfilarial Counts at 1 Year</measure>
    <time_frame>1 year from time enrolled</time_frame>
    <description>Night time microfilarial counts at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adult Worm Burdens at 2 Years</measure>
    <time_frame>2 years from the time enrolled.</time_frame>
    <description>Doppler detected worm nests at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microfilarial Levels at 2 Years</measure>
    <time_frame>2 years from time enrolled</time_frame>
    <description>Night time microfilarial levels at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brugia Specific Immunoglobulin G4 (IgG4) Antibodies</measure>
    <time_frame>2 years</time_frame>
    <description>IgG4 antibodies directed against Brugia malayi antigen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <arm_group>
    <arm_group_label>Diethylcarbamazine/Albendazole -STD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard therapy of DEC (300mg) and albendazole (400mg) yearly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diethylcarbamazine/Albendazole- HD1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose of DEC (300mg) and albendazole (800mg) yearly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diethylcarbamazine/Albendazole-HD2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Comparing 400 mg to 800 mg dose</description>
    <arm_group_label>Diethylcarbamazine/Albendazole -STD</arm_group_label>
    <arm_group_label>Diethylcarbamazine/Albendazole- HD1</arm_group_label>
    <arm_group_label>Diethylcarbamazine/Albendazole-HD2</arm_group_label>
    <other_name>Zentel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <description>Providing diethylcarbamazine more frequently in combination with albendazole</description>
    <arm_group_label>Diethylcarbamazine/Albendazole -STD</arm_group_label>
    <arm_group_label>Diethylcarbamazine/Albendazole- HD1</arm_group_label>
    <arm_group_label>Diethylcarbamazine/Albendazole-HD2</arm_group_label>
    <other_name>Banocide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Inclusion Criteria for Screening:

          -  Age 18 years to 55 years inclusive

          -  Both genders

          -  Not pregnant or breastfeeding by history

          -  If selected, subjects must be willing to spend 3 days on the Filariasis Chemotherapy
             Unit at the T.D. Medical College Hospital, Alleppey, Kerala, India

          -  If selected, subjects must be willing to undergo nighttime blood draws once every 6
             months and Doppler ultrasound twice yearly for 2 years

          -  If selected, agree to have blood stored for future studies

          -  Ability to understand and give informed consent

        Inclusion Criteria for Treatment:

          -  Age 18 to 55 years inclusive

          -  Men and non-pregnant or non-breast feeding women

          -  Microfilarial levels greater than 50mf/mL

          -  Willingness to spend 3 days on the Filariasis Chemotherapy Unit at the T.D. Medical
             College Hospital, Alleppey, Kerala, India every 6 months for 2 years

          -  Willingness to undergo nighttime blood draws once every 6 months for 2 years

          -  Ability to understand and give informed consent

          -  Hemaglobin (Hgb) levels for inclusion greater than 9 g/dL

          -  Creatinine (Cr) less than or equal to 1.2 mg/dL

          -  Alanine aminotransferase (ALT) less than 30 U/L

          -  Willingness to have blood stored for future studies

        EXCLUSION CRITERIA:

        Exclusion Criteria for Screening:

          -  Age less than 18 years or greater than 55 years

          -  Pregnant or breast feeding by history

        Exclusion Criteria for Treatment:

          -  Non-volunteers

          -  Age less than 18 years or greater than 55 years

          -  Pregnant or breast feeding

          -  Hgb levels less than or equal to 9 g/dL

          -  Cr greater than 1.3 mg/dL

          -  ALT greater than 30 U/L

          -  Alcohol consumption of more than 2 beers or other alcohol-containing drinks/day within
             a week of each drug administration

          -  Temperature greater than 37.5 degrees Celsius

          -  Serious medical illness

          -  History of benzimidazole allergy

          -  History of DEC allergy

          -  Use of albendazole or DEC within past 6 months

          -  Unwillingness to comply with required study visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas B Nutman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Filariasis Chemotherapy Unit (FCU), T.D. Medical Hospital</name>
      <address>
        <city>Alleppey, Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Edwards G, Awadzi K, Breckenridge AM, Gilles HM, Orme ML, Ward SA. Diethylcarbamazine disposition in patients with onchocerciasis. Clin Pharmacol Ther. 1981 Oct;30(4):551-7.</citation>
    <PMID>7285488</PMID>
  </reference>
  <reference>
    <citation>Taylor HR, Greene BM. Ocular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasis. Br J Ophthalmol. 1981 Jul;65(7):494-502.</citation>
    <PMID>7020746</PMID>
  </reference>
  <reference>
    <citation>Partono F, Purnomo, Oemijati S, Soewarta A. The long term effects of repeated diethylcarbamazine administration with special reference to microfilaraemia and elephantiasis. Acta Trop. 1981 Sep;38(3):217-25.</citation>
    <PMID>6118029</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <results_first_submitted>July 2, 2015</results_first_submitted>
  <results_first_submitted_qc>July 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2015</results_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brugia Malayi</keyword>
  <keyword>Lymphatic Filariasis</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Diethylcarbamazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults living in Kerala, India with Brugia malayi microfilaremia were recruited from field sites around the city of Alleppey and the study performed in the outpatient department of the TD Medical College.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Therapy Annual DEC/ALB</title>
          <description>Group randomized to standard therapy that consists of Annual diethylcarbamazine (300 mg) and albendazole (400mg)</description>
        </group>
        <group group_id="P2">
          <title>High Dose Annual DEC/ALB</title>
          <description>Group randomized to yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
        </group>
        <group group_id="P3">
          <title>High Dose Semiannual DEC/ALB</title>
          <description>Group randomized to twice-yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Therapy Annual DEC/ALB</title>
          <description>Group randomized to standard therapy that consists of Annual diethylcarbamazine (300 mg) and albendazole (400mg)</description>
        </group>
        <group group_id="B2">
          <title>High Dose Annual DEC/ALB</title>
          <description>Group randomized to yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
        </group>
        <group group_id="B3">
          <title>High Dose Semiannual DEC/ALB</title>
          <description>Group randomized to twice-yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B2" value="39" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B3" value="37" lower_limit="19" upper_limit="54"/>
                    <measurement group_id="B4" value="37" lower_limit="18" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood microfilaremia (mf/ml)</title>
          <units>MF/ML</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="412" lower_limit="64" upper_limit="912"/>
                    <measurement group_id="B2" value="264" lower_limit="112" upper_limit="1244"/>
                    <measurement group_id="B3" value="384" lower_limit="108" upper_limit="748"/>
                    <measurement group_id="B4" value="384" lower_limit="64" upper_limit="1244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Microfilarial Counts at 1 Year</title>
        <description>Night time microfilarial counts at 1 year</description>
        <time_frame>1 year from time enrolled</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy Annual DEC/ALB</title>
            <description>Group randomized to standard therapy that consists of Annual diethylcarbamazine (300 mg) and albendazole (400mg)</description>
          </group>
          <group group_id="O2">
            <title>High Dose Annual DEC/ALB</title>
            <description>Group randomized to yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
          </group>
          <group group_id="O3">
            <title>High Dose Semiannual DEC/ALB</title>
            <description>Group randomized to twice-yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Microfilarial Counts at 1 Year</title>
          <description>Night time microfilarial counts at 1 year</description>
          <units>MF/ML</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.2</p_value>
            <p_value_desc>Adjusted for multiple comparisons</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adult Worm Burdens at 2 Years</title>
        <description>Doppler detected worm nests at 2 years</description>
        <time_frame>2 years from the time enrolled.</time_frame>
        <population>By 2 years, 4 subjects in High Dose Group lost to followup</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy Annual DEC/ALB</title>
            <description>Group randomized to standard therapy that consists of Annual diethylcarbamazine (300 mg) and albendazole (400mg)</description>
          </group>
          <group group_id="O2">
            <title>High Dose Annual DEC/ALB</title>
            <description>Group randomized to yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
          </group>
          <group group_id="O3">
            <title>High Dose Semiannual DEC/ALB</title>
            <description>Group randomized to twice-yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Adult Worm Burdens at 2 Years</title>
          <description>Doppler detected worm nests at 2 years</description>
          <population>By 2 years, 4 subjects in High Dose Group lost to followup</population>
          <units>Number of nests</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microfilarial Levels at 2 Years</title>
        <description>Night time microfilarial levels at 2 years</description>
        <time_frame>2 years from time enrolled</time_frame>
        <population>By 2 years, 4 subjects in High Dose Group lost to followup</population>
        <group_list>
          <group group_id="O1">
            <title>Diethylcarbamazine/Albendazole -STD</title>
            <description>Standard therapy of diethylcarbamazine (DEC) (300mg) and albendazole (400mg) yearly
Albendazole: Comparing 400 mg to 800 mg dose
Diethylcarbamazine: Providing diethylcarbamazine more frequently in combination with albendazole</description>
          </group>
          <group group_id="O2">
            <title>Diethylcarbamazine/Albendazole- HD1</title>
            <description>High dose of DEC (300mg) and albendazole (800mg) yearly
Albendazole: Comparing 400 mg to 800 mg dose
Diethylcarbamazine: Providing diethylcarbamazine more frequently in combination with albendazole</description>
          </group>
          <group group_id="O3">
            <title>Diethylcarbamazine/Albendazole-HD2</title>
            <description>High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
Albendazole: Comparing 400 mg to 800 mg dose
Diethylcarbamazine: Providing diethylcarbamazine more frequently in combination with albendazole</description>
          </group>
        </group_list>
        <measure>
          <title>Microfilarial Levels at 2 Years</title>
          <description>Night time microfilarial levels at 2 years</description>
          <population>By 2 years, 4 subjects in High Dose Group lost to followup</population>
          <units>MF/ML</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brugia Specific Immunoglobulin G4 (IgG4) Antibodies</title>
        <description>IgG4 antibodies directed against Brugia malayi antigen</description>
        <time_frame>2 years</time_frame>
        <population>By 2 years, 4 subjects in High Dose Group lost to followup</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy Annual DEC/ALB</title>
            <description>Group randomized to standard therapy that consists of Annual diethylcarbamazine (300 mg) and albendazole (400mg)</description>
          </group>
          <group group_id="O2">
            <title>High Dose Annual DEC/ALB</title>
            <description>Group randomized to yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
          </group>
          <group group_id="O3">
            <title>High Dose Semiannual DEC/ALB</title>
            <description>Group randomized to twice-yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Brugia Specific Immunoglobulin G4 (IgG4) Antibodies</title>
          <description>IgG4 antibodies directed against Brugia malayi antigen</description>
          <population>By 2 years, 4 subjects in High Dose Group lost to followup</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" lower_limit="0" upper_limit="1000"/>
                    <measurement group_id="O2" value="224" lower_limit="0" upper_limit="2100"/>
                    <measurement group_id="O3" value="128" lower_limit="0" upper_limit="650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Every 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Therapy Annual DEC/ALB</title>
          <description>Group randomized to standard therapy that consists of Annual diethylcarbamazine (300 mg) and albendazole (400mg)</description>
        </group>
        <group group_id="E2">
          <title>High Dose Annual DEC/ALB</title>
          <description>Group randomized to yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
        </group>
        <group group_id="E3">
          <title>High Dose Semiannual DEC/AC=LB</title>
          <description>Group randomized to twice-yearly high dose albendazole that consists of Annual diethylcarbamazine (300 mg) and albendazole (800mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Custom</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study never fully enrolled so sample size was smaller than hoped for.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas B. Nutman</name_or_title>
      <organization>NIAID</organization>
      <phone>301-496-5398</phone>
      <email>tnutman@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

